Cetuximab plus irinotecan in pretreated metastatic colorectal cancer patients: The ELSIE study
文献类型：期刊论文
| 刊名 | WORLD JOURNAL OF GASTROENTEROLOGY
 |
| 出版日期 | 2011 |
| 卷号 | 17 |
| 关键词 | GROWTH-FACTOR-RECEPTOR PHASE-II TRIAL FLUOROURACIL FAILURE 1ST-LINE TREATMENT RANDOMIZED-TRIAL CHEMOTHERAPY OXALIPLATIN EXPRESSION INFUSION SURVIVAL Epidermal growth factor receptor Cetuximab Irinotecan Metastatic colorectal cancer Asia |
| ISSN号 | 1007-9327 |
| 其他题名 | Cetuximab plus irinotecan in pretreated metastatic colorectal cancer patients: The ELSIE study |
| 英文摘要 | AIM: To evaluate the efficacy and safety of cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer (mCRC) patients from South-East Asia and Australia. |
| 资助项目 | [Merck KGaA, Darmstadt, Germany] |
| 语种 | 英语 |
| CSCD记录号 | CSCD:4190079 |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/52186]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 推荐引用方式 GB/T 7714 | . Cetuximab plus irinotecan in pretreated metastatic colorectal cancer patients: The ELSIE study[J]. WORLD JOURNAL OF GASTROENTEROLOGY,2011,17. |
| APA | (2011).Cetuximab plus irinotecan in pretreated metastatic colorectal cancer patients: The ELSIE study.WORLD JOURNAL OF GASTROENTEROLOGY,17. |
| MLA | "Cetuximab plus irinotecan in pretreated metastatic colorectal cancer patients: The ELSIE study".WORLD JOURNAL OF GASTROENTEROLOGY 17(2011). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。